published meta-analysis   sensitivity analysis   studies

potential COVID-19 treatments in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias Emergency room visit or hospitalizationdetailed resultsACTIV-6, 2022 1.10 [0.64; 1.91] ACTIV-6 (ivermectine), 2023 0.94 [0.58; 1.53] COVID-OUT (fluvoxamine), 2022 1.17 [0.57; 2.40] COVID-OUT (ivermectin), 2022 1.39 [0.72; 2.69] COVID-OUT (metformin), 2022 0.58 [0.35; 0.95] 0.95[0.70; 1.29]ACTIV-6, 2022, ACTIV-6 (ivermectine), 2023, COVID-OUT (fluvoxamine), 2022, COVID-OUT (ivermectin), 2022, COVID-OUT (metformin), 2022530%3,966moderatenot evaluable death D28detailed resultsC3PO, 2020 5.02 [0.58; 43.27] Clemency, 2021 1.03 [0.02; 52.20] COMET-ICE, 2021 0.25 [0.01; 5.55] CoV-Early (Gharbharan), 2022 1.01 [0.06; 16.25] EPIC-HR, 2021 0.04 [0.00; 0.70] Ezer N (CONTAIN), 2021 0.93 [0.02; 47.48] Fischer (all doses), 2021 0.22 [0.01; 6.60] MOVe-OUT, 2021 0.06 [0.00; 1.05] PINETREE (GS-US-540-9012), 2021 1.01 [0.02; 51.30] PRINCIPLE (COLCHICINE), 2021 0.42 [0.01; 12.75] TOGETHER, 2021 0.69 [0.37; 1.30] University of Minnesota, 2021 1.02 [0.02; 52.15] 0.63[0.37; 1.07]C3PO, 2020, Clemency, 2021, COMET-ICE, 2021, CoV-Early (Gharbharan), 2022, EPIC-HR, 2021, Ezer N (CONTAIN), 2021, Fischer (all doses), 2021, MOVe-OUT, 2021, PINETREE (GS-US-540-9012), 2021, PRINCIPLE (COLCHICINE), 2021, TOGETHER, 2021, University of Minnesota, 2021120%8,101moderatelow deathsdetailed resultsACTIV-6 (ivermectine), 2023 2.01 [0.07; 59.98] BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 1.15 [0.02; 58.61] BLAZE-1 phase 3 (combo), 2021 0.05 [0.00; 0.84] C3PO, 2020 5.02 [0.58; 43.27] Clemency, 2021 1.03 [0.02; 52.20] COLCORONA, 2021 0.56 [0.19; 1.66] COMET-ICE, 2021 0.25 [0.01; 5.55] CONV-ERT, 2021 0.20 [0.01; 4.07] COPE – Coalition V, 2022 1.56 [0.39; 6.24] Cov-2067 Weinreich (1200mg) Cohort 1, 2020 0.45 [0.05; 3.82] Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 1.01 [0.02; 51.05] CoV-Early (Gharbharan), 2022 1.01 [0.06; 16.25] COVID-PEP Severity (Skipper), 2020 1.01 [0.06; 16.28] EPIC-HR, 2021 0.04 [0.00; 0.70] Ezer N (CONTAIN), 2021 0.93 [0.02; 47.48] Fischer (all doses), 2021 0.22 [0.01; 6.60] IVERCORCOVID19 (Vallejos), 2020 1.34 [0.30; 6.03] Lopez-Medina, 2021 0.50 [0.02; 14.95] MOVe-OUT, 2021 0.06 [0.00; 1.05] PATCH Cohort 1 (Amaravadi), 2021 0.86 [0.02; 46.71] PINETREE (GS-US-540-9012), 2021 1.01 [0.02; 51.30] PRINCIPLE, 2021 1.65 [0.03; 83.12] PRINCIPLE (COLCHICINE), 2021 0.42 [0.01; 12.75] Reis (Hydroxychloroquine) (TOGETHER), 2021 0.26 [0.01; 5.88] Thomas (vitamin c only), 2021 2.11 [0.07; 64.28] Thomas (vitamin c plus zinc), 2021 3.54 [0.16; 80.27] TOGETHER, 2021 0.80 [0.43; 1.50] TOGETHER (ivermectine), 2022 0.87 [0.48; 1.58] University of Minnesota, 2021 1.02 [0.02; 52.15] 0.77[0.56; 1.07]ACTIV-6 (ivermectine), 2023, BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, BLAZE-1 phase 3 (combo), 2021, C3PO, 2020, Clemency, 2021, COLCORONA, 2021, COMET-ICE, 2021, CONV-ERT, 2021, COPE – Coalition V, 2022, Cov-2067 Weinreich (1200mg) Cohort 1, 2020, Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021, CoV-Early (Gharbharan), 2022, COVID-PEP Severity (Skipper), 2020, EPIC-HR, 2021, Ezer N (CONTAIN), 2021, Fischer (all doses), 2021, IVERCORCOVID19 (Vallejos), 2020, Lopez-Medina, 2021, MOVe-OUT, 2021, PATCH Cohort 1 (Amaravadi), 2021, PINETREE (GS-US-540-9012), 2021, PRINCIPLE, 2021, PRINCIPLE (COLCHICINE), 2021, Reis (Hydroxychloroquine) (TOGETHER), 2021, Thomas (vitamin c only), 2021, Thomas (vitamin c plus zinc), 2021, TOGETHER, 2021, TOGETHER (ivermectine), 2022, University of Minnesota, 2021290%24,544lowlow deaths (time to event analysis only)detailed resultsTOGETHER, 2021 0.80 [0.43; 1.50] 0.80[0.43; 1.50]TOGETHER, 202110%1,472NAnot evaluable hospitalization or deathdetailed resultsACTIV 6 ivermectin, 2022 1.05 [0.43; 2.61] ALBERTA HOPE-Covid19, 2021 2.73 [0.14; 52.87] BLAZE-1 phase 2 (combination with etesevimab), 2020 0.15 [0.02; 1.18] BLAZE-1 phase 2 (monotherapy), 2020 0.16 [0.02; 1.31] BLAZE-1 phase 3 (combo), 2021 0.29 [0.15; 0.58] C3PO, 2020 0.91 [0.63; 1.33] Clemency, 2021 0.39 [0.09; 1.67] COLCORONA, 2021 0.79 [0.61; 1.03] COMET-ICE, 2021 0.21 [0.09; 0.49] Cov-2067 Weinreich (1200mg) Cohort 1, 2020 0.29 [0.12; 0.68] COVID-OUT (fluvoxamine), 2022 1.11 [0.33; 3.75] COVID-OUT (ivermectin), 2022 0.73 [0.19; 2.79] COVID-OUT (metformin), 2022 0.47 [0.20; 1.11] EPIC-HR, 2021 0.12 [0.06; 0.24] Hinks (ATOMIC2), 2021 0.91 [0.43; 1.92] IVERCORCOVID19 (Vallejos), 2020 0.66 [0.33; 1.30] MOVe-OUT, 2021 0.48 [0.30; 0.78] PINETREE (GS-US-540-9012), 2021 0.13 [0.03; 0.58] PRINCIPLE, 2021 0.81 [0.58; 1.13] PRINCIPLE (COLCHICINE), 2021 1.29 [0.36; 4.67] TOGETHER, 2021 0.76 [0.57; 1.02] 0.53[0.41; 0.70]ACTIV 6 ivermectin, 2022, ALBERTA HOPE-Covid19, 2021, BLAZE-1 phase 2 (combination with etesevimab), 2020, BLAZE-1 phase 2 (monotherapy), 2020, BLAZE-1 phase 3 (combo), 2021, C3PO, 2020, Clemency, 2021, COLCORONA, 2021, COMET-ICE, 2021, Cov-2067 Weinreich (1200mg) Cohort 1, 2020, COVID-OUT (fluvoxamine), 2022, COVID-OUT (ivermectin), 2022, COVID-OUT (metformin), 2022, EPIC-HR, 2021, Hinks (ATOMIC2), 2021, IVERCORCOVID19 (Vallejos), 2020, MOVe-OUT, 2021, PINETREE (GS-US-540-9012), 2021, PRINCIPLE, 2021, PRINCIPLE (COLCHICINE), 2021, TOGETHER, 20212167%21,647moderatecritical A EFFACER PCR-negative (end of follow-up)detailed resultsHinks (ATOMIC2), 2021 0.91 [0.57; 1.46] 0.91[0.57; 1.46]Hinks (ATOMIC2), 202110%295NAnot evaluable clinical deteriorationdetailed resultsCOMET-ICE, 2021 0.24 [0.10; 0.56] COVID-OUT (fluvoxamine), 2022 0.94 [0.65; 1.35] COVID-OUT (ivermectin), 2022 1.05 [0.76; 1.45] COVID-OUT (metformin), 2022 0.84 [0.65; 1.08] Lenze (STOP COVID 1), 2020 0.07 [0.00; 1.26] Lopez-Medina, 2021 0.56 [0.16; 1.95] PATCH Cohort 1 (Amaravadi), 2021 0.51 [0.07; 3.68] TOGETHER, 2021 0.64 [0.47; 0.87] TOGETHER (ivermectine), 2022 0.90 [0.70; 1.16] 0.77[0.62; 0.97]COMET-ICE, 2021, COVID-OUT (fluvoxamine), 2022, COVID-OUT (ivermectin), 2022, COVID-OUT (metformin), 2022, Lenze (STOP COVID 1), 2020, Lopez-Medina, 2021, PATCH Cohort 1 (Amaravadi), 2021, TOGETHER, 2021, TOGETHER (ivermectine), 2022954%7,245moderateserious clinical improvementdetailed resultsACTIV 6 ivermectin, 2022 1.07 [0.97; 1.18] COVID-PEP Severity (Skipper), 2020 1.36 [0.87; 2.11] Lopez-Medina, 2021 1.07 [0.87; 1.32] PRINCIPLE, 2021 1.21 [1.08; 1.36] PRINCIPLE, 2021 1.08 [0.95; 1.23] Thomas (vitamin c only), 2021 3.14 [0.60; 16.38] Thomas (vitamin c plus zinc), 2021 0.85 [0.27; 2.65] 1.12[1.05; 1.19]ACTIV 6 ivermectin, 2022, COVID-PEP Severity (Skipper), 2020, Lopez-Medina, 2021, PRINCIPLE, 2021, PRINCIPLE, 2021, Thomas (vitamin c only), 2021, Thomas (vitamin c plus zinc), 202170%5,694moderatenot evaluable clinical improvement (14-day)detailed resultsACTION, 2021 1.01 [0.75; 1.37] Clemency, 2021 1.19 [0.78; 1.81] COVID-PEP Severity (Skipper), 2020 1.36 [0.87; 2.11] 1.13[0.91; 1.40]ACTION, 2021, Clemency, 2021, COVID-PEP Severity (Skipper), 202030%1,058moderatenot evaluable clinical improvement (21-day)detailed resultsLopez-Medina, 2021 1.28 [0.79; 2.10] 1.28[0.79; 2.10]Lopez-Medina, 202110%400NAnot evaluable clinical improvement (28-day)detailed resultsACTIV 6 ivermectin, 2022 1.07 [0.97; 1.18] Clemency, 2021 1.28 [0.84; 1.96] 1.08[0.98; 1.19]ACTIV 6 ivermectin, 2022, Clemency, 202120%1,991lownot evaluable clinical improvement (7-day)detailed resultsClemency, 2021 0.92 [0.51; 1.66] Thomas (vitamin c only), 2021 3.14 [0.60; 16.38] 1.32[0.44; 3.94]Clemency, 2021, Thomas (vitamin c only), 2021247%498lownot evaluable clinical improvement (time to event analysis only)detailed resultsACTIV 6 ivermectin, 2022 1.07 [0.97; 1.18] Lopez-Medina, 2021 1.07 [0.87; 1.32] PRINCIPLE, 2021 1.08 [0.95; 1.23] 1.07[1.00; 1.16]ACTIV 6 ivermectin, 2022, Lopez-Medina, 2021, PRINCIPLE, 202130%3,314lownot evaluable hospitalizationdetailed resultsACTIV-6, 2022 0.45 [0.04; 5.03] ACTIV-6 (ivermectine), 2023 2.01 [0.37; 11.03] BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 0.75 [0.32; 1.76] Buonfrate (COVER-HIGH DOSE ARM C), 2022 6.33 [0.30; 132.38] C3PO, 2020 0.88 [0.57; 1.34] COLCORONA, 2021 0.79 [0.60; 1.04] COMET-ICE, 2021 0.20 [0.08; 0.48] CONV-ERT, 2021 1.05 [0.78; 1.41] COPE – Coalition V, 2022 0.77 [0.52; 1.13] Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 0.08 [0.00; 1.49] CoV-Early (Gharbharan), 2022 0.61 [0.28; 1.33] COVID-OUT (fluvoxamine), 2022 1.11 [0.33; 3.75] COVID-OUT (ivermectin), 2022 0.73 [0.19; 2.79] Ezer N (CONTAIN), 2021 1.92 [0.47; 7.89] Hinks (ATOMIC2), 2021 0.95 [0.46; 1.96] IVERCORCOVID19 (Vallejos), 2020 0.65 [0.32; 1.32] MOVe-OUT, 2021 0.49 [0.30; 0.79] PATCH Cohort 1 (Amaravadi), 2021 1.79 [0.06; 57.93] PINETREE (GS-US-540-9012), 2021 0.28 [0.10; 0.77] PRINCIPLE, 2021 0.94 [0.50; 1.75] PRINCIPLE (COLCHICINE), 2021 1.73 [0.43; 7.07] Reis (Hydroxychloroquine) (TOGETHER), 2021 0.76 [0.30; 1.90] Rodrigues, 2021 2.02 [0.07; 62.02] Roozbeh, 2020 0.23 [0.02; 2.21] Thomas (vitamin c only), 2021 0.68 [0.11; 4.27] Thomas (vitamin c plus zinc), 2021 2.15 [0.53; 8.80] TOGETHER, 2021 0.76 [0.57; 1.02] TOGETHER (ivermectine), 2022 0.81 [0.59; 1.11] University of Minnesota, 2021 3.16 [0.32; 31.34] 0.78[0.67; 0.90]ACTIV-6, 2022, ACTIV-6 (ivermectine), 2023, BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, Buonfrate (COVER-HIGH DOSE ARM C), 2022, C3PO, 2020, COLCORONA, 2021, COMET-ICE, 2021, CONV-ERT, 2021, COPE – Coalition V, 2022, Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021, CoV-Early (Gharbharan), 2022, COVID-OUT (fluvoxamine), 2022, COVID-OUT (ivermectin), 2022, Ezer N (CONTAIN), 2021, Hinks (ATOMIC2), 2021, IVERCORCOVID19 (Vallejos), 2020, MOVe-OUT, 2021, PATCH Cohort 1 (Amaravadi), 2021, PINETREE (GS-US-540-9012), 2021, PRINCIPLE, 2021, PRINCIPLE (COLCHICINE), 2021, Reis (Hydroxychloroquine) (TOGETHER), 2021, Rodrigues, 2021, Roozbeh, 2020, Thomas (vitamin c only), 2021, Thomas (vitamin c plus zinc), 2021, TOGETHER, 2021, TOGETHER (ivermectine), 2022, University of Minnesota, 20212922%20,417lowlow mechanical ventilationdetailed resultsC3PO, 2020 1.49 [0.25; 9.02] COLCORONA, 2021 0.53 [0.25; 1.11] COPE – Coalition V, 2022 1.32 [0.46; 3.79] IVERCORCOVID19 (Vallejos), 2020 1.34 [0.30; 6.03] PRINCIPLE, 2021 0.50 [0.10; 2.60] PRINCIPLE, 2021 1.02 [0.45; 2.33] 0.85[0.55; 1.30]C3PO, 2020, COLCORONA, 2021, COPE – Coalition V, 2022, IVERCORCOVID19 (Vallejos), 2020, PRINCIPLE, 2021, PRINCIPLE, 202160%9,480moderatenot evaluable Recovery (time to event analysis only)detailed resultsACTIV-6 (ivermectine), 2023 1.02 [0.92; 1.13] Buonfrate (COVER-HIGH DOSE ARM C), 2022 0.79 [0.42; 1.48] 1.01[0.92; 1.12]ACTIV-6 (ivermectine), 2023, Buonfrate (COVER-HIGH DOSE ARM C), 202220%1,270lownot evaluable symptomatic Covid-19detailed resultsCov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 0.56 [0.31; 1.00] 0.56[0.31; 1.00]Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 202110%204NAnot evaluable viral clearance detailed resultsBLAZE-1 phase 2 (combination with etesevimab), 2020 1.65 [0.91; 3.00] BLAZE-1 phase 2 (monotherapy), 2020 0.67 [0.33; 1.38] Chaccour, 2020 0.92 [0.77; 1.09] Fischer (all doses), 2021 14.50 [1.70; 123.69] Q-PROTECT (HCQ/AZI vs PLACEBO), 2020 0.86 [0.46; 1.61] Reis (Hydroxychloroquine) (TOGETHER), 2021 0.92 [0.82; 1.03] Rodrigues, 2021 1.00 [0.42; 2.39] TOGETHER, 2021 0.67 [0.42; 1.06] 0.93[0.77; 1.11]BLAZE-1 phase 2 (combination with etesevimab), 2020, BLAZE-1 phase 2 (monotherapy), 2020, Chaccour, 2020, Fischer (all doses), 2021, Q-PROTECT (HCQ/AZI vs PLACEBO), 2020, Reis (Hydroxychloroquine) (TOGETHER), 2021, Rodrigues, 2021, TOGETHER, 2021845%1,856moderatenot evaluable viral clearance by day 14detailed resultsIVERCORCOVID19 (Vallejos), 2020 0.76 [0.45; 1.28] Q-PROTECT (HCQ/AZI vs PLACEBO), 2020 0.55 [0.32; 0.94] Reis (Hydroxychloroquine) (TOGETHER), 2021 0.92 [0.82; 1.03] 0.79[0.59; 1.07]IVERCORCOVID19 (Vallejos), 2020, Q-PROTECT (HCQ/AZI vs PLACEBO), 2020, Reis (Hydroxychloroquine) (TOGETHER), 2021348%1,173moderatenot evaluable viral clearance by day 7detailed resultsBLAZE-1 phase 2 (combination with etesevimab), 2020 1.31 [0.61; 2.83] BLAZE-1 phase 2 (monotherapy), 2020 0.91 [0.39; 2.09] Chaccour, 2020 0.92 [0.77; 1.09] Feld, 2021 4.12 [1.08; 15.71] Fischer (all doses), 2021 14.50 [1.70; 123.69] Q-PROTECT (HCQ/AZI vs PLACEBO), 2020 0.86 [0.46; 1.61] Rodrigues, 2021 1.00 [0.42; 2.39] TOGETHER, 2021 0.67 [0.42; 1.06] TOGETHER (ivermectine), 2022 0.99 [0.59; 1.67] 1.00[0.76; 1.31]BLAZE-1 phase 2 (combination with etesevimab), 2020, BLAZE-1 phase 2 (monotherapy), 2020, Chaccour, 2020, Feld, 2021, Fischer (all doses), 2021, Q-PROTECT (HCQ/AZI vs PLACEBO), 2020, Rodrigues, 2021, TOGETHER, 2021, TOGETHER (ivermectine), 2022943%1,862moderatenot evaluable emergency room observation for > 6 hours or hospitalizationdetailed resultsTOGETHER, 2021 0.64 [0.47; 0.87] 0.64[0.47; 0.87]TOGETHER, 202110%1,497NAnot evaluable ICU admissiondetailed resultsCOPE – Coalition V, 2022 0.84 [0.43; 1.63] PRINCIPLE, 2021 0.54 [0.24; 1.21] PRINCIPLE, 2021 0.76 [0.18; 3.18] University of Minnesota, 2021 1.02 [0.06; 16.66] 0.72[0.45; 1.15]COPE – Coalition V, 2022, PRINCIPLE, 2021, PRINCIPLE, 2021, University of Minnesota, 202140%4,097moderatenot evaluable recoverydetailed resultsACTIV-6, 2022 0.96 [0.86; 1.07] Ezer N (CONTAIN), 2021 1.25 [0.71; 2.22] PRINCIPLE, 2021 1.21 [1.08; 1.36] PRINCIPLE (COLCHICINE), 2021 0.92 [0.72; 1.17] 1.05[0.89; 1.24]ACTIV-6, 2022, Ezer N (CONTAIN), 2021, PRINCIPLE, 2021, PRINCIPLE (COLCHICINE), 2021469%4,275moderatenot evaluable AE leading to drug discontinuationdetailed resultsFischer (all doses), 2021 0.88 [0.08; 9.94] MOVe-OUT, 2021 0.49 [0.23; 1.05] PINETREE (GS-US-540-9012), 2021 0.40 [0.08; 2.09] TOGETHER, 2021 1.38 [0.98; 1.95] 0.79[0.37; 1.69]Fischer (all doses), 2021, MOVe-OUT, 2021, PINETREE (GS-US-540-9012), 2021, TOGETHER, 2021460%3,672moderatenot evaluable emergent treatment-resistant variantsdetailed resultsBLAZE-1 phase 2 (combination with etesevimab), 2020 0.18 [0.02; 1.51] BLAZE-1 phase 2 (monotherapy), 2020 1.52 [0.51; 4.47] 0.64[0.08; 4.94]BLAZE-1 phase 2 (combination with etesevimab), 2020, BLAZE-1 phase 2 (monotherapy), 2020267%497moderatenot evaluable related AE (TRAE)detailed resultsCOLCORONA, 2021 1.74 [1.50; 2.03] EPIC-HR, 2021 1.76 [1.10; 2.82] 1.74[1.51; 2.01]COLCORONA, 2021, EPIC-HR, 202120%5,761lownot evaluable related SAE (TRSAE)detailed resultsEPIC-HR, 2021 1.01 [0.25; 4.05] 1.01[0.25; 4.05]EPIC-HR, 202110%1,349NAnot evaluable serious adverse eventsdetailed resultsCOLCORONA, 2021 0.77 [0.60; 1.00] Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 0.25 [0.03; 2.23] Fischer (all doses), 2021 1.34 [0.14; 13.10] Lenze (STOP COVID 1), 2020 0.17 [0.02; 1.49] Lopez-Medina, 2021 1.00 [0.14; 7.17] MOVe-OUT, 2021 0.70 [0.48; 1.03] PINETREE (GS-US-540-9012), 2021 0.25 [0.09; 0.69] 0.66[0.49; 0.89]COLCORONA, 2021, Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021, Fischer (all doses), 2021, Lenze (STOP COVID 1), 2020, Lopez-Medina, 2021, MOVe-OUT, 2021, PINETREE (GS-US-540-9012), 2021720%7,450lownot evaluable adverse eventsdetailed resultsBCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 178.20 [73.71; 430.85] Chaccour, 2020 1.00 [0.20; 5.07] COMET-ICE, 2021 0.91 [0.68; 1.22] Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 0.55 [0.34; 0.86] COVID-PEP Severity (Skipper), 2020 2.75 [1.80; 4.21] Ezer N (CONTAIN), 2021 0.82 [0.43; 1.57] Fischer (all doses), 2021 1.05 [0.54; 2.02] Lenze (STOP COVID 1), 2020 0.98 [0.40; 2.38] MOVe-OUT, 2021 0.89 [0.71; 1.11] PINETREE (GS-US-540-9012), 2021 0.85 [0.61; 1.19] 1.59[0.86; 2.93]BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, Chaccour, 2020, COMET-ICE, 2021, Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021, COVID-PEP Severity (Skipper), 2020, Ezer N (CONTAIN), 2021, Fischer (all doses), 2021, Lenze (STOP COVID 1), 2020, MOVe-OUT, 2021, PINETREE (GS-US-540-9012), 20211094%4,690moderatelow0.25.01.0relative treatment effectwww.metaEvidence.org2024-04-18 03:03 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439 - roots T: 290